Myriad Genetics (MYGN) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Myriad Genetics (MYGN) as a "perilous reversal" (up big yesterday but down big today) candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Myriad Genetics

(

MYGN

) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Myriad Genetics as such a stock due to the following factors:

  • MYGN has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $48.4 million.
  • MYGN has traded 124,744 shares today.
  • MYGN is down 3% today.
  • MYGN was up 9.1% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MYGN with the Ticky from Trade-Ideas. See the FREE profile for MYGN NOW at Trade-Ideas

More details on MYGN:

Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. MYGN has a PE ratio of 39. Currently there are 5 analysts that rate Myriad Genetics a buy, 2 analysts rate it a sell, and 6 rate it a hold.

The average volume for Myriad Genetics has been 961,600 shares per day over the past 30 days. Myriad has a market cap of $2.9 billion and is part of the services sector and diversified services industry. The stock has a beta of -0.17 and a short float of 65.1% with 24.62 days to cover. Shares are up 35.5% year-to-date as of the close of trading on Wednesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Myriad Genetics as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and increase in net income. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from the ratings report include:

  • MYGN's revenue growth has slightly outpaced the industry average of 4.8%. Since the same quarter one year prior, revenues slightly increased by 8.7%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • MYGN has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 4.07, which clearly demonstrates the ability to cover short-term cash needs.
  • Compared to where it was a year ago today, the stock is now trading at a higher level, reflecting both the market's overall trend during that period and the fact that the company's earnings growth has been robust. Turning our attention to the future direction of the stock, it goes without saying that even the best stocks can fall in an overall down market. However, in any other environment, this stock still has good upside potential despite the fact that it has already risen in the past year.
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Biotechnology industry. The net income increased by 66.4% when compared to the same quarter one year prior, rising from $15.98 million to $26.60 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...